Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odiparcil - Inventiva Pharma

Drug Profile

Odiparcil - Inventiva Pharma

Alternative Names: 424323; IVA336; SB 424323

Latest Information Update: 16 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fournier Pharma
  • Developer Fournier Pharma; GlaxoSmithKline; Inventiva Pharma; Solvay
  • Class Antiarrhythmics; Antithrombotics; Benzopyrans; Glycosides; Ketones; Organic sulfur compounds; Small molecules; Vascular disorder therapies
  • Mechanism of Action Glycosaminoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VI
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VI
  • Discontinued Atrial fibrillation; Deep vein thrombosis; Stroke; Thrombosis

Most Recent Events

  • 16 Feb 2022 Inventiva intends to provide development update on Odiparcil, in 2022
  • 31 Dec 2021 Suspended - Phase-II for Mucopolysaccharidosis VI in Germany, Portugal, France, United Kingdom (PO), as The company focuses on the development of lanifibranor, prior to December 2021
  • 31 Dec 2021 Suspended - Preclinical for Mucopolysaccharidosis I in France (PO), as The company focuses on the development of lanifibranor, prior to December 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top